The use of Tylenol by girls throughout pregnancy was not related with autism in their kids, in accordance with outcomes of a nationwide study in Denmark revealed on Monday.
Among greater than 1.5 million kids born between 1997 and 2022, together with 31,098 uncovered to Tylenol in the womb, autism was later recognized in 1.8% of uncovered kids and three% of the unexposed group, Danish researchers reported in JAMA Pediatrics.
The lack of an affiliation endured after researchers accounted for particular person danger components together with the dose of the drug and the trimester of pregnancy in which it was used, the report mentioned.
A 2024 Swedish study additionally discovered no hyperlink between autism and pregnancy use of Tylenol, a model title for acetaminophen and paracetamol.
A 2025 review by U.S. researchers of 46 earlier research did recommend a doable hyperlink between prenatal acetaminophen publicity and neurodevelopmental problems equivalent to autism and a spotlight deficit hyperactivity dysfunction in kids, however the researchers mentioned the study does not show the drug induced these circumstances. They suggested that pregnant girls ought to proceed to make use of acetaminophen as wanted, on the lowest doable dose and for the shortest doable interval.
In September, the U.S. Food and Drug Administration mentioned it was initiating the method for a label change for acetaminophen to warn that its use by pregnant girls could also be related with an elevated danger of autism and ADHD. At the time of the FDA announcement, U.S. President Donald Trump mentioned pregnant girls and infants should not take the drug due to its hyperlink with autism.
Since then, nationwide and worldwide medical teams have decried the president’s comments, saying they had been not evidence-based.
A month after the FDA mentioned it will advocate limiting Tylenol use in pregnancy, U.S. Health Secretary Robert F. Kennedy, Jr. mentioned evidence does not show that Tylenol definitively causes autism however that it ought to nonetheless be used cautiously.
The FDA declined to touch upon the standing of its deliberate label change.